Logistics and Regulatory Challenges in Overseas Specimen Transport
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 23, 2016
- Reading time: 2 minutes
Currently, we are managing a case that involves transporting blood specimens directly to Japan. We would like to share the various components required for this process: contracts with Japanese clinical laboratories, selection of logistics providers, and navigating the regulatory landscape of Taiwan. Fundamentally, Medical Supporter's role is to resolve these complexities for patients seeking immunotherapy at Japanese clinics or participation in clinical trial programs by leveraging our established professional network.
Regarding the international transport of specimens, time is of the essence. After intensive negotiations, we have successfully secured contracts with Japanese clinical laboratories. On the logistics front, we have finalized arrangements with DHL for all necessary medical consumables and contractual procedures. The remaining challenge lies in obtaining approvals from the Ministry of Health and Welfare (MOHW) and coordinating with technically qualified domestic partners. The primary bottleneck is the MOHW review process, which is estimated to take approximately 18 working days. Furthermore, whether specific clinical trial units will accept this transport model requires ongoing, detailed negotiations.
For reference, we previously shared information regarding CAR-T Cell therapy. While we provide comprehensive data to assist patients, the decision to pursue such experimental treatments must be carefully evaluated by the individuals themselves.
Additionally, we recommend referring to the Wall Street Journal's report on CAR-T cell therapy for further technical context.
The following illustration outlines the mechanism of action. We will introduce more details in our next update.
Note: Medical Supporter provides translations of overseas clinical trial data and pharmaceutical information. This content is for informational purposes only and does not constitute an endorsement or solicitation for specific clinical trials or new drug usage. For inquiries regarding specific clinical trials, patients may contact the respective units directly or reach out to our team for professional assistance.
HP: http://www.medicalsupporter.org Tel: 090-5563-717 Skype & LINE: medicalsupporter Mail: service@medicalsupporter.org
Medical Supporter Work Note #Immunotherapy
- Medical Supporter Work Note
- (Melanoma) Efficacy of Pembrolizumab (Keytruda)?
- Anti-Cancer Battle: Living Without Fear
- Work Note: University of Tokyo Institute of Medical Science Hospital
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4